Show simple item record

dc.contributor.authorHerukka, Sanna-Kaisa
dc.contributor.authorSimonsen, Anja Hviid
dc.contributor.authorAndreasen, Niels
dc.contributor.authorBaldeiras, Ines
dc.contributor.authorBjerke, Maria
dc.contributor.authorBlennow, Kaj
dc.contributor.authorEngelborghs, Sebastiaan
dc.contributor.authorFrisoni, Giovanni B.
dc.contributor.authorGabryelewicz, Tomasz
dc.contributor.authorGalluzzi, Samantha
dc.contributor.authorHandels, Ron
dc.contributor.authorKramberger, Milica G.
dc.contributor.authorKulczynska, Agnieszka
dc.contributor.authorLuis Molinuevo, Jose
dc.contributor.authorMroczko, Barbara
dc.contributor.authorNordberg, Agneta
dc.contributor.authorOliveira, Catarina Resende
dc.contributor.authorOtto, Markus
dc.contributor.authorRinne, Juha O.
dc.contributor.authorRot, Uros
dc.contributor.authorSaka, Esen
dc.contributor.authorSoininen, Hilkka
dc.contributor.authorStruyfs, Hanne
dc.contributor.authorSuardi, Silvia
dc.contributor.authorVisser, Pieter Jelle
dc.contributor.authorWinblad, Bengt
dc.contributor.authorZetterberg, Henrik
dc.contributor.authorWaldemar, Gunhild
dc.date.accessioned2019-12-10T11:25:51Z
dc.date.available2019-12-10T11:25:51Z
dc.date.issued2017
dc.identifier.issn1552-5260
dc.identifier.urihttps://doi.org/10.1016/j.jalz.2016.09.009
dc.identifier.urihttp://hdl.handle.net/11655/15728
dc.description.abstractThis article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3)interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre-and post-biomarker counseling. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.isversionof10.1016/j.jalz.2016.09.009
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectNeurosciences & Neurology
dc.titleRecommendations for Cerebrospinal Fluid Alzheimer'S Disease Biomarkers in The Diagnostic Evaluation of Mild Cognitive Impairment
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalAlzheimers & Dementia
dc.contributor.departmentNöroloji
dc.identifier.volume13
dc.identifier.issue3
dc.identifier.startpage285
dc.identifier.endpage295
dc.description.indexWoS


Files in this item

This item appears in the following Collection(s)

Show simple item record